CDMO – Talk Bio

Lonza, Wolfgang Wienand, CDMO, Pharmaceutical manufacturing, Biologics, Cell and gene therapy, Small molecules, Leadership transition, Industry outlook

Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France

8 months ago talkbio0Tagged alpha 1-antitrypsin, Axplora, biology (field), CDMO, Chromatography, Diabetes, expansion, France, Glucagon-Like Peptide 1, Manufacturing, Mourenx, Obesity, production

Axplora, GLP-1, manufacturing expansion, Mourenx, France, CDMO, API production, chromatography, diabetes, obesity, biologic therapies

Rentschler Biopharma Exits Cell and Gene Therapy Sector, Refocuses on Biologics Manufacturing

9 months ago talkbio0Tagged Biological Factors, Biopharma, CDMO, Cells, Demand (clinical), gene therapy, Manufacturing, Market, Rentschler, Stevenage facility closure, strategic realignment

Rentschler Biopharma, strategic realignment, cell and gene therapy, biologics manufacturing, CDMO, market demand, Stevenage facility closure

Samsung Biologics Achieves Record Revenue and Secures Largest Contract to Date

9 months ago talkbio0Tagged Biological Factors, Biosimilars, CDMO, Contract agreement, Drug Industry, Largest, Revenue, Samsung

Samsung Biologics, Record Revenue, Largest Contract, Biosimilars, CDMO, Pharmaceutical Industry

Charles River Laboratories Forecasts Revenue Decline in 2025 Amid CDMO Challenges

9 months ago talkbio0Tagged 2025, Biopharma, business career, CDMO, Charles, constraints, Drug Industry, IL31RA gene, revenue outlook, River Laboratories, spending, trends qualifier

Charles River Laboratories, CRL, 2025 revenue outlook, CDMO business challenges, biopharma spending constraints, pharmaceutical industry trends

Samsung Biologics Embarks on New Phase of Growth with Bio Campus II and ADC Services

9 months ago talkbio0Tagged Antibody-Drug Conjugates, Bio Campus II, Biological Factors, Capacity, CDMO, Contract agreement, development aspects, digital transformation, expansion, Manufacturing Organization, Plants, Samsung, Services

Samsung Biologics, Bio Campus II, Plant 5, antibody-drug conjugate (ADC) services, capacity expansion, digital transformation, contract development and manufacturing organization (CDMO)